India’s drug regulator, the CDSCO, has approved the drug Ozempic for type 2 diabetes management, despite its global off-label use for weight loss. This approval intensifies competition in the GLP segment, with Munjaro having been approved for diabetes and obesity in March 2025. The stock market is seeing varied performance, with Hindustan Unilever emerging as a top loser. A speaker noted, "the commentary from HUL has been on the conservative side, they are basically talking about sort of, you know, a sort of unchanged performance compared to last quarter in the second quarter." In contrast, the telecom sector, including HFCL and Tejas Networks, is performing well following a BSNL 4G inauguration. The market is also watching Q-commerce and auto stocks like Tata Motors, which is benefiting from a British government loan, for a festive season boost.
#ozempicindia #cdsco #diabetes #itwebvideos #indiatoday #stockmarket #hul #fmcg #tatamotors #telecom #qcommerce #festiveseason #businessnews #pharma #indiatoday #marketupdate #indianeconomy
Subscribe to India Today for NEW VIDEOS EVERY DAY and make sure to enable Push Notifications so you’ll never miss a new video.
All you need to do is PRESS THE BELL ICON next to the Subscribe button!
India Today TV is India’s leading English News Channel. India Today YouTube channel offers latest news videos on Politics, Business, Cricket, Bollywood, Lifestyle, Auto, Technology, Travel, Entertainment and a lot more.
Stay tuned for latest updates and in-depth analysis of news from India and around the world!
WhatsApp Channel: https://whatsapp.com/channel/0029Va2AnW3JENxxg7OuJv00
Download App: https://indiatoday.link/wHaj
Follow us: Official website: https://www.indiatoday.in/
Twitter: https://twitter.com/IndiaToday
Facebook: https://www.facebook.com/IndiaToday
